| Literature DB >> 33319078 |
Beatha Nyirandagijimana1, Alphonse Nshimyiryo1, Hildegarde Mukasakindi1, Jackline Odhiambo2,3, Eugenie Uwimana2, Valerie Mukamurenzi2, Robert Bienvenu1, Jean Sauveur Ndikubwimana2, Clemence Uwamaliya2, Priya Kundu1, Paul H Park4,5,6, Tharcisse Mpunga2, Giuseppe J Raviola4,5,7, Fredrick Kateera1, Christian Rusangwa1, Stephanie L Smith4,5,8.
Abstract
BACKGROUND: Integrating epilepsy care into primary care settings could reduce the global burden of illness attributable to epilepsy. Since 2012, the Rwandan Ministry of Health and the international nonprofit Partners In Health have collaboratively used a multi-faceted implementation program- MESH MH-to integrate and scale-up care for epilepsy and mental disorders within rural primary care settings in Burera district, Rwanda. We here describe demographics, service use and treatment patterns for patients with epilepsy seeking care at MESH-MH supported primary care health centers. METHODS ANDEntities:
Keywords: Epilepsy; Health systems research; Mental health; Neurology; Operational research; Primary care integration
Year: 2020 PMID: 33319078 PMCID: PMC7724371 DOI: 10.1016/j.ensci.2020.100296
Source DB: PubMed Journal: eNeurologicalSci ISSN: 2405-6502
Characteristics of people with and without epilepsy receiving neurologic and mental health care at MESH-MH supported health centers in Burera District, Rwanda, January 2015 to January 2016.
| Persons with epilepsy diagnosis n (%) | Non-epilepsy diagnosis n (%) | |
|---|---|---|
| Gender ( | ||
| | 163 (57.0) | 189 (35.8) |
| | 123 (43.0) | 339 (64.2) |
| Age group ( | ||
| | 72 (26.8) | 13 (2.7) |
| | 68 (25.3) | 54 (11.1) |
| | 129 (48.0) | 418 (86.2) |
| Distance from home to the health facility ( | ||
| | 235 (88.3) | 448 (90.0) |
| | 31 (11.7) | 50 (10.0) |
| Comorbidity ( | ||
| | 256 (90%) | – |
| | 3 (1%) | – |
| | 7 (2%) | – |
| | 20 (7%) | – |
Treatment regimens (n = 283)a
| Anti-epileptic medication | N (%) |
|---|---|
| Carbamazepine/Tegretol | 97 (34.2) |
| Phenobarbital | 70 (24.7) |
| Depakine/Depakote | 71 (25.1) |
| Other | 7 (2.5) |
| Polytherapy | 38 (13.4) |
Medication data were missing for three patients.
Patient follow up visit attendance by diagnosis.
| Visit | Epilepsy diagnosis | Non-epilepsy diagnosis | Total | P-value | |||
|---|---|---|---|---|---|---|---|
| n | % returning (n/N) | n | % returning (n/N) | n | % returning (n/N) | ||
| Initial visit | 286 | – | 529 | – | 815 | – | – |
| Second visit | 233 | 81.5% (233/286) | 375 | 70.9% (375/529) | 608 | 74.6% (608/815) | <0.01 |
| Fifth visit | 167 | 58.3% (167/286) | 241 | 45.5% (241/529) | 408 | 50.1% (408/815) | <0.01 |
Second visit defined as occurring within 90 days of first visit
Each visit from second to fifth occurred within 90 days of the previous visit
Predictors of attendance at a second and fifth visit for people with epilepsy⁎,⁎⁎
| 2nd Visit | 5th Visit | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Attended n (%) | Did not attend, n(%) | Unadjusted Odds Ratio [95% CI] | Unadjusted p-value | Adjusted Odds Ratio [95%CI] | Adjusted p-value | Attended n (%) | Did not attend, n(%) | Unadjusted Odds Ratio [95% CI] | Unadjusted p-value | Odds Ratio [95%CI] | p-value | |
| Gender (n = 286) | ||||||||||||
| | 130 (55.8) | 33 (62.3) | 94 (56.3) | 69 (58.0) | ||||||||
| | 103 (44.2) | 20 (37.7) | 1.31 [0.68–2.55] | 0.44 | 1.66 [0.79–3.45] | 0.18 | 73 (43.7) | 50 (42.0) | 1.07 [0.65–1.77] | 0.81 | 1.18 [0.69–2.00] | 0.55 |
| Age group ( | ||||||||||||
| | 61 (27.6) | 11 (22.9) | 1.28 [0.59–2.97] | 0.59 | 1.39 [0.61–3.15] | 0.18 | 47 (29.7) | 25 (22.5) | 1.45 [0.80–2.67] | 0.21 | 1.35 [0.74–2.47] | 0.32 |
| | 54 (24.4) | 14 (29.2) | 0.79 [0.38–1.71] | 0.58 | 0.92 [0.41–2.05] | 0.83 | 41 (26.0) | 27 (24.3) | 1.09 [0.60–2.00] | 0.78 | 1.36 [0.73–2.53] | 0.033 |
| | 106 (48.0) | 23 (47.9) | 1.00 [0.51–1.97] | 1.00 | 0.83 [0.22–1.91] | 0.43 | 70 (44.3) | 59 (53.2) | 00.70 [0.42–1.18] | 0.17 | 0.63 [0.37–1.06] | 0.08 |
| Distance from home to health facility ( | ||||||||||||
| | 197 (89.1) | 38 (84.4) | 146 (91.2) | 89 (84.0) | ||||||||
| | 24 (10.9) | 7 (15.6) | 0.66 [0.25–1.95] | 0.44 | 0.65 [0.22–1.91] | 0.43 | 14 (8.8) | 17 (16.0) | 0.50 [0.22–1.14] | 0.08 | 0.53 [0.23–1.24] | 0.14 |
| Comorbidity (n = 286) | ||||||||||||
| | 209 (89.7) | 47 (88.7) | 147 (88.0) | 109 (91.6) | ||||||||
| | 24 (10.3) | 6 (11.3) | 0.99 [0.35–2.49] | 1.00 | 1.05 [0.40–2.78] | 0.92 | 20 (12.0) | 10 (8.4) | 0.90 [0.42–1.91] | 0.86 | 0.96 [0.46–2.03] | 0.93 |
Odds ratios and p-values based on both Fisher tests of pairwise variable associations (“unadjusted”) and a multiple logistic regression involving all predictors (“adjusted”).
Although the effect of distance on fifth-visit attendance does not reach statistical significance in analysis of people with epilepsy alone, when all patients are analyzed the effect of distance is highly significant (p < 0.01). There is no interaction between epilepsy diagnosis and distance (p = 0.9 in a separate multiple logistic regression analysis not shown here), so it would be justified to base analysis of the effect of distance on the entire patient population.